AstraZeneca's AZD0780 cuts LDL-C by 50% in Phase IIb trial
The treatment helped 84% of participants reach the recommended LDL-C target, compared to just 13% with statins alone.
The PURSUIT trial sought to compare the placebo to the company's first oral small molecule modulator, designed for the treatment of dyslipidemia, when used alongside lipid-lowering statin therapy, the current standard of care in many cholesterol-related conditions.
The primary endpoint of the dose-finding trial sought to measure the effect of different doses of AZD0780 given once daily across differing levels of LDL-C in patients, with similar levels of efficacy observed regardless of whether patients had received moderate or high-intensity statin doses at the time of baseline measurement.
The therapy comes in response to research published in the journal Postgraduate Medicine that estimates as much as 70% of patients globally are currently not reaching guideline-recommended LDL-C targets.
The results were announced as part of the American College of Cardiology's (ACC) Annual Scientific Expo in Chicago and suggest AZD0780 could provide a new, convenient option for patients struggling to meet cholesterol goals despite existing therapies.
The trial's principal investigator Michael J Koren said: 'The PURSUIT Phase IIb trial demonstrates the potential of AZD0780 to provide a much-needed once-daily oral treatment option to deliver greater LDL cholesterol lowering on top of standard of care for millions of patients who remain at risk for serious cardiovascular events, including premature death.
'These results are particularly important because the majority of patients with atherosclerotic disease today do not reach their LDL-C goals, despite the availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors.'
Research by GlobalData estimates that should AZD0780 make it to market it is predicted to bring in $46m for AstraZeneca, with that figure forecasted to grow to $462m by the end of 2031.
GlobalData is the parent company of Clinical Trials Arena.
AstraZeneca's executive vice president Sharon Barr said: 'These new data reflect AZD0780's ability to reduce LDL cholesterol in patients who need more options to manage their cholesterol and related risks when standard-of-care therapy is not enough.'
Elsewhere at the ACC Annual Expo, Cleerly has announced interim results from a trial, described as the largest-ever cardiovascular phenotype outcomes study, finding that women living with chronic coronary artery disease (CAD) are at higher risk of major adverse coronary events.
Meanwhile, Eli Lilly has reported promising Phase II results for lepodisiran, its experimental therapy aimed at reducing lipoprotein(a).
"AstraZeneca's AZD0780 cuts LDL-C by 50% in Phase IIb trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
BofA Securities Affirms ‘Buy' Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is . On July 11, BofA Securities initiated coverage of the stock with a 'Buy' rating and an $8 price target. The positive stance comes as the research firm remains buoyed by the company's Taysha gene therapy TSHA-102 under development for Rett Syndrome. Copyright: dolgachov / 123RF Stock Photo The research firm believes TSHA-102 has the potential to become the first approved disease-modifying treatment for the severe neurodevelopmental disease. Clinical trials have already demonstrated that the therapy has the potential to help patients regain or achieve developmental milestones. Taysha Gene Therapies has already reached an alignment with the US Food and Drug Administration on a pivotal trial design for TSHA-102. The company plans to initiate a trial in the third quarter of 2023. BofA Securities views the candidate treatment as a commercially attractive opportunity. Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a clinical-stage biotech company focused on developing and bringing to market gene therapies for serious monogenic disorders affecting the central nervous system. It seeks to address unmet medical needs by developing transformative medicines for these diseases. Its approach centers on using adeno-associated virus (AAV)-based gene therapies. While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Children's charity sees demand for services triple
A charity that supports children with mental health disorders said demand for its services has tripled since the Covid pandemic. KidsAid, which is based in Northampton and works across the Midlands and south east of England, provides long-term, trauma-specialised therapeutic support to children. In 2024-25 the charity worked with 495 children in comparison to 2021-21 when it supported 163 children. Carla Managan, the clinical lead at the charity, said: "A lot of children never returned to school [after the pandemic], and selective mutism has risen too. "It surrounds anxiety about going back to school – many of these children struggled in school before the pandemic, then their anxiety increased during the time schools closed." The charity said it planned to deliver 4,500 therapy sessions to more than 500 children and families this year. Mrs Managan said the charity's staff has more than tripled in size since the pandemic. "During Covid, we had eight therapists and two staff members. Now there are 25 therapists and 10 staff members. We are expanding all the time," she said. The charity said in 2024 more than 60% of referrals it received were due to children being exposed to abuse, either experiencing it directly or witnessing others being abused. It costs KidsAid about £2,200 to provide 26 weeks of one-to-one therapy for a child. The charity said it received no statutory or public health funding, instead its services were financed through a combination of community and corporate fundraising, grants from trusts and foundations and some families contributing to sessions. KidsAid said it currently received an average of 50 unfunded referrals each month, children in crisis who need help, but whom the charity lacks the money to support. It said it seeks contributions from schools or applies for grants to support these referrals, but due to an increase in demand it cannot always support every unfunded referral. Melisha Pillay has been a foster carer for three years and she sought support from KidsAid for one of the children in her care. The child was given art therapy in her school for a year to help her understand and learn about emotions. Ms Pillay said: "The art therapy allowed her to just feel more comfortable and be able to access emotions sometimes through colour, pictures, movement." The success of the therapy has led to the child being reunited with her dad, Ms Pillay said. She added that the child was now able to "express the emotion of sadness when she felt sad, but then also able to understand that we can hold two emotions". Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X. More like this Primary school pupils going for mental health gold Primary school lessons to focus on mental health Youth music project 'boosts mental wellbeing' Related internet links KidsAid
Forbes
11 hours ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
